The role of fibrinogen and fibrinolysis in peripheral arterial disease.
Peripheral arterial disease (PAD) is associated with high rates of cerebrovascular and cardiovascular events; PAD is a marker of systemic atherosclerosis. As a result, standard therapy for all PAD patients should be directed at both peripheral and systemic atherosclerosis. Modification of established risk factors in the form of smoking cessation, correcting hypertension, optimizing diabetic control and normalizing lipids is essential. Furthermore, novel risk factors have emerged including fibrinogen and other hemostatic factors. Fibrinogen is a coagulation factor and a marker of the acute phase response (inflammation), a platelet activator, a major determinant of plasma viscosity and a component of the atherosclerotic plaque. Fibrinogen appears not only to predict the severity of PAD, but also serves as a marker for future development of PAD. Whether reducing the levels of fibrinogen and other coagulation factors will decrease the incidence and progression of PAD remains to be resolved. This review summarizes the role of fibrinogen in the pathogenesis of PAD and its association with other hemostatic factors. The role of fibrinolysis in patients with PAD is also considered.
Department of Clinical Biochemistry and Academic Department of Surgery, Royal Free Hospital, London, UK. paraskevask@hotmail.com
Kosmas I
KI
Paraskevas
Daryll M
DM
Baker
George E
GE
Vrentzos
Dimitri P
DP
Mikhailidis
D017677:Age Distribution; D000368:Aged; D050197:Atherosclerosis / Q000209:etiology; D005340:Fibrinogen / Q000502:physiology*; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015994:Incidence; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000401:mortality
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005340:Fibrinogen